Kerendia™ (finerenone) – New drug approval
July 9, 2021 - The FDA announced the approval of Bayer’s Kerendia (finerenone), to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).
Top